Mifeprestone for Treatment of Hypercortisolism

Author(s):

Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE,Ralph DeFronzo, MD

Experts discuss the CATALYST study's evaluation of mifepristone for hypercortisolism patients with hard-to-manage type 2 diabetes, its mechanism of action, suitable patient populations, treatment approaches for those with adrenal tumors, and factors determining surgical candidacy.

EP: 1.Overview of the CATALYST Study for Hypercortisolism

EP: 2.Defining Difficult to Control Diabetes

EP: 3.CATALYST Trial Study Design

EP: 4.True Prevalence of Hypercortisolism

EP: 5.Coexisting Cardiometabolic Conditions and Hypercortisolism

EP: 6.Engaging Primary Care Clinicians in Screening for Hypercortisolism

EP: 7.Spectrum of Hypercortisolism Presentations

Now Viewing

EP: 8.Mifeprestone for Treatment of Hypercortisolism

EP: 9.Reconsidering Standard of Care for Hypercortisolism

Video content above is prompted by the following:

• Part 2 of the CATALYST study will assess the safety and efficacy of mifepristone treatment in patients with hypercortisolism who have difficult-to-control type 2 diabetes. Can you explain how mifepristone works to control hypercortisolism? For which patients would this treatment be appropriate?
• The catalyst study also showed that a quarter of the patients with hypercortisolism had an adrenal tumor. What would be the best way to treat these patients?
• Which patients would not be good candidates for surgery?